Vial Adapter with and without filter ישראל - עברית - Ministry of Health

vial adapter with and without filter

medimop medical projects ltd. - אחות - the vial adapter is intended for efficient, safe and fast transfer of diluents/reconstituted drugs from/into vials

קוג'נייט FS 500 IU ישראל - עברית - Ministry of Health

קוג'נייט fs 500 iu

bayer israel ltd - antihemophilic factor (recombinant) sucrose - אבקה להכנת תמיסה לזריקה - antihemophilic factor (recombinant) sucrose 500 iu/vial - blood coagulation factors - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor viii.routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with severe hemophilia a with no pre-existing joint damage. kogenate fs is not indicated for the treatment of von willebrand’s disease.

אללייזו ישראל - עברית - Ministry of Health

אללייזו

pfizer pharmaceuticals israel ltd - taliglucerase alfa - אבקה להכנת תמיסה לאינפוזיה - taliglucerase alfa 200 u/vial - taliglucerase alfa - taliglucerase alfa - elelyso (taliglucerase alfa ) for injection is a hydrolytic lysosomal glucocerebroside - specific enzyme indicated for long - term enzyme replacement therapy (ert) for adults with a confirmed diagnosis of type 1 gaucher disease.

קוג'נייט FS 1000 IU ישראל - עברית - Ministry of Health

קוג'נייט fs 1000 iu

bayer israel ltd - antihemophilic factor (recombinant) sucrose - אבקה להכנת תמיסה לזריקה - antihemophilic factor (recombinant) sucrose 1000 iu/vial - blood coagulation factors - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor viii.routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children under with severe hemophilia a with no pre-existing joint damage.kogenate fs is not indicated for the treatment of von willebrand’s disease.

ספראבטו ישראל - עברית - Ministry of Health

ספראבטו

j-c health care ltd - esketamine as hydrochloride - esketamine as hydrochloride 28 mg/vial - esketamine

דנטריום תוך ורידי 20 מג'/בקבוקון ישראל - עברית - Ministry of Health

דנטריום תוך ורידי 20 מג'/בקבוקון

neopharm ltd - dantrolene sodium 20 mg/vial - powder for solution for injection - dantrolene - for the management of fulminant hypermetabolism of skeletal muscle characteristic of malignent hyperthermia (mh) crises in patients of all ages

קוג'נייט FS 250 IU ישראל - עברית - Ministry of Health

קוג'נייט fs 250 iu

bayer israel ltd - antihemophilic factor (recombinant) sucrose 250 iu/vial - powder for solution for injection - blood coagulation factors - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor viii.routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with severe hemophilia a with no pre-existing joint damage.kogenate fs is not indicated for the treatment of von willebrand’s disease.

biopince-biopsy gun&coaxial introducer n ישראל - עברית - Ministry of Health

biopince-biopsy gun&coaxial introducer n

nim ltd. - רופא - אקדח לביופסיה לרקמות רכות ומחטי מעבר לביופסיה

רמיקד ישראל - עברית - Ministry of Health

רמיקד

j-c health care ltd - infliximab 100 mg/vial - powder for concentrate for infusion - infliximab - - adult :crohn's disease: treatment of severe active crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. treatment of fistulising crohn's disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. -paediatric crohn's disease: remicade is indicated for: treatment of severe active crohn's disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. remicade has been studied only in combination with conventional immunosuppressive therapy -ankylosing spondylitis: remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional ther